Biomarker | Median value (range) | Endpoint | < Median value | ≥ Median value | HR* (95% CI) | p | ||
---|---|---|---|---|---|---|---|---|
n | Median time to event, weeks | n | Median time to event, weeks | |||||
Median maximal percent change in biomarker concentration from C1D1 to C2D28 | ||||||||
sKIT | 48.6% (−) | TTP | 30 | 7.9 | 31 | 21.7 | 5.99 (3.06-11.7) | < 0.0001 |
 |  | OS |  | 25.7 |  | 53.7 | 2.33 (1.16-4.70) | 0.018 |
VEGF-A | 89.4% (−) | TTP | 30 | 9.9 | 31 | 10.3 | 1.75 (0.99-3.09) | 0.054 |
 |  | OS |  | 32.3 |  | 62.6 | 2.12 (1.06-4.23) | 0.032 |
sVEGFR-2 | 55.8% (−) | TTP | 30 | 10.1 | 31 | 10.2 | 1.07 (0.62-1.85) | 0.81 |
 |  | OS |  | 36.0 |  | 53.7 | 1.52 (0.76-3.02) | 0.24 |
sVEGFR-3 | 52.8% (−) | TTP | 27 | 10.1 | 28 | 11.0 | 1.40 (0.77-2.52) | 0.27 |
 |  | OS |  | 51.6 |  | 52.7 | 1.98 (0.79-4.96) | 0.15 |
Median baseline biomarker concentration | ||||||||
sKIT | 70 ng/mL (26–113) | TTP | 28 | 10.6 | 28 | 10.1 | 1.08 (0.60-1.96) | 0.80 |
 |  | OS |  | 37.4 |  | 45.1 | 1.13 (0.55-2.35) | 0.74 |
VEGF-A | 53 pg/mL (14–709) | TTP | 25 | 10.1 | 26 | 10.2 | 0.71 (0.38-1.33) | 0.29 |
 |  | OS |  | Not reached |  | 33.0 | 0.55 (0.25-1.22) | 0.14 |
sVEGFR-2 | 11 ng/mL (4–15) | TTP | 28 | 10.3 | 28 | 10.1 | 0.98 (0.54-1.76) | 0.94 |
 |  | OS |  | 37.4 |  | 62.6 | 1.19 (0.57-2.46) | 0.65 |
sVEGFR-3 | 68 ng/mL (25–152) | TTP | 28 | 10.1 | 28 | 10.2 | 0.97 (0.54-1.75) | 0.93 |
 |  | OS |  | 37.4 |  | 53.7 | 1.43 (0.68-2.98) | 0.35 |